S&P 500   5,087.03
DOW   39,069.11
QQQ   438.07
Top-Rated AMD nears major breakout level
The Strategic Gold Play You Haven't Heard About (Ad)
Roku stock and the mother of all entry opportunities
AI powerhouse NVIDIA will hit $1000 soon
The Strategic Gold Play You Haven't Heard About (Ad)
Nvidia, Royal Caribbean rise; Rivian, Etsy fall, Thursday, 2/22/2024
The Trade Desk: 3 reasons to buy before a new all-time high
Americans Now Favor Gold Over Stocks as an Investment Vehicle (Ad)
Rivian shares gets discounted; shares can move lower 
Wall Street sees a solid year ahead for homebuilders, though mortgage rates remain a wildcard
S&P 500   5,087.03
DOW   39,069.11
QQQ   438.07
Top-Rated AMD nears major breakout level
The Strategic Gold Play You Haven't Heard About (Ad)
Roku stock and the mother of all entry opportunities
AI powerhouse NVIDIA will hit $1000 soon
The Strategic Gold Play You Haven't Heard About (Ad)
Nvidia, Royal Caribbean rise; Rivian, Etsy fall, Thursday, 2/22/2024
The Trade Desk: 3 reasons to buy before a new all-time high
Americans Now Favor Gold Over Stocks as an Investment Vehicle (Ad)
Rivian shares gets discounted; shares can move lower 
Wall Street sees a solid year ahead for homebuilders, though mortgage rates remain a wildcard
S&P 500   5,087.03
DOW   39,069.11
QQQ   438.07
Top-Rated AMD nears major breakout level
The Strategic Gold Play You Haven't Heard About (Ad)
Roku stock and the mother of all entry opportunities
AI powerhouse NVIDIA will hit $1000 soon
The Strategic Gold Play You Haven't Heard About (Ad)
Nvidia, Royal Caribbean rise; Rivian, Etsy fall, Thursday, 2/22/2024
The Trade Desk: 3 reasons to buy before a new all-time high
Americans Now Favor Gold Over Stocks as an Investment Vehicle (Ad)
Rivian shares gets discounted; shares can move lower 
Wall Street sees a solid year ahead for homebuilders, though mortgage rates remain a wildcard
S&P 500   5,087.03
DOW   39,069.11
QQQ   438.07
Top-Rated AMD nears major breakout level
The Strategic Gold Play You Haven't Heard About (Ad)
Roku stock and the mother of all entry opportunities
AI powerhouse NVIDIA will hit $1000 soon
The Strategic Gold Play You Haven't Heard About (Ad)
Nvidia, Royal Caribbean rise; Rivian, Etsy fall, Thursday, 2/22/2024
The Trade Desk: 3 reasons to buy before a new all-time high
Americans Now Favor Gold Over Stocks as an Investment Vehicle (Ad)
Rivian shares gets discounted; shares can move lower 
Wall Street sees a solid year ahead for homebuilders, though mortgage rates remain a wildcard

Astellas Pharma (ALPMY) Earnings Date, Estimates & Call Transcripts

$10.96
-0.16 (-1.44%)
(As of 02/22/2024 ET)
Skip Charts & View Estimated and Actual Earnings Data

ALPMY Earnings Estimates and Actuals by Quarter

The chart below shows up to four years of a company's earnings history. The dark blue line represents the company's actual earnings per share. The light blue area represents the range of Wall Street analysts' earnings estimates for each quarter.

ALPMY Estimated and Actual Revenue by Quarter

The chart below shows up to four years of a company's revenue history. The dark blue line represents the company's actual revenue. The light blue line represents the company's estimated revenue based on the consensus of Wall Street analysts for each quarter.

Astellas Pharma Analyst EPS Estimates

Current Year EPS Consensus Estimate:$0.31 EPS
Next Year EPS Consensus Estimate: $0.62 EPS

Astellas Pharma Earnings History by Quarter

DateQuarterConsensus EstimateReported EPSBeat/MissGAAP EPSRevenue EstimateActual RevenueCall Transcript
11/1/2023Q3 2023$0.17($0.01)($0.18)($0.01)-$2.71 billion  
8/1/2023Q2 2023$0.22$0.13($0.09)$0.13-$2.73 billion
4/27/2023Q4 2023-$0.15+$0.15$0.49-$2.68 billion
2/6/2023Q3 2023-$0.27+$0.27$0.35-$2.85 billion
10/31/2022Q2 2023-$0.28+$0.28$0.28-$2.76 billion
8/1/2022Q1 2023-$0.10+$0.10$0.10-$2.95 billion
4/27/2022Q4 2022-($0.04)($0.04)($0.04)-$2.62 billion
2/2/2022Q3 2022-$0.34+$0.34$0.39-$3.00 billion
10/29/2021Q2 2022-$0.20+$0.20$0.20-$2.96 billion
7/30/2021Q1 2022-$0.15+$0.15$0.15-$2.98 billion
4/27/2021Q1 2021$0.22($0.06)($0.28)($0.06)-$2.91 billion












Astellas Pharma Earnings - Frequently Asked Questions

How much revenue does Astellas Pharma generate each year?

Astellas Pharma (OTCMKTS:ALPMY) has a recorded annual revenue of $11.24 billion.

How much profit does Astellas Pharma generate each year?

Astellas Pharma (OTCMKTS:ALPMY) has a recorded net income of $742 million. ALPMY has generated $0.00 earnings per share over the last four quarters.

What is Astellas Pharma's price-to-earnings ratio?

Astellas Pharma (OTCMKTS:ALPMY) has a trailing price-to-earnings ratio of 28.51 and a forward price-to-earnings ratio of 35.35. The price/earnings-to-growth ratio is 2.65.

What is Astellas Pharma's EPS forecast for next year?

Astellas Pharma's earnings are expected to grow from $0.31 per share to $0.62 per share in the next year, which is a 100.00% increase.


More Earnings Resources from MarketBeat

This page (OTCMKTS:ALPMY) was last updated on 2/23/2024 by MarketBeat.com Staff